The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). “This positive CHMP opinion is a welcome advancement for physicians and patients in Europe ...

I found purpose after my AML diagnosis by reflecting on loss, embracing gratitude and using my experience to help others ...

The treatment of leukemia among children could be made more precise with fewer side effects with the help of more accurate ...

Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease Concurrently performed, our trial's primary ...

About 3 out of 4 leukemia cases among children and teens are acute lymphocytic leukemia and most of the remaining cases are acute myeloid leukemia. Dig deeper: Acute lymphocytic leukemia is the ...

The diagnosis, prognosis, treatment indication, response criteria, and adverse events were recorded as per International Workshop on Chronic Lymphocytic Leukemia guidelines. Biosimilar rituximab ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

The therapy is already in practical use for patients of acute lymphocytic leukemia and malignant lymphoma. The team created some 14,000 antibodies against AML cells and discovered cells from among ...